Drug Profile
Research programme: antibody drug conjugates - Collaborations Pharmaceuticals/Rutgers University/University of North Carolina
Alternative Names: Antituberculars - Collaborations Pharmaceuticals/Rutgers UniversityLatest Information Update: 22 Jun 2023
Price :
$50
*
At a glance
- Originator Collaborations Pharmaceuticals; RTI International; Rutgers; University of North Carolina at Chapel Hill
- Class Antibacterials; Antibodies; Antituberculars; Drug conjugates; Small molecules
- Mechanism of Action 3 Oxoacyl (acyl carrier protein) synthase modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 22 Jun 2023 Preclinical development is ongoing USA (Collaborations pharmaceuticals, pipeline June 2023)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Tuberculosis in USA (Inhalation)
- 06 Jan 2020 Antibody drug conjugates - Collaborations Pharmaceuticals/Rutgers University/University of North Carolina is available for licensing as of 06 Jan 2020. http://www.collaborationspharma.com/pipeline